A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume
Source abstract
Abstract
We crosslink hemoglobin (Hb), superoxide dismutase (SOD), catalase (CAT), and carbonic anhydrase (CA) to form a soluble polyHb-SOD-CAT-CA nanobiotechnological complex. The obtained product is a soluble complex with three enhanced red blood cell (RBC) functions and without blood group antigens. In the present study, 2/3 of blood volume was removed to result in 90-min hemorrhagic shock at mean arterial blood pressure (MAP) of 30 mmHg. This was followed by the reinfusion of different resuscitation fluids, then followed for another 60 min. PolyHb-SOD-CAT-CA maintained the MAP at 87.5 ± 5 mmHg as compared with 3 volumes of lactated Ringer's solution, 43.3 ± 2.8 mmHg; blood, 91.3 ± 3.6 mmHg; polyHb-SOD-CAT, 86.0 ± 4.6 mmHg; poly stroma-free hemolysate (polySFHb), 85.0 ± 2.5 mmHg; and polyHb, 82.6 ± 3.5 mmHg. PolyHb-SOD-CAT-CA was superior to the blood and other fluids based on the following criteria. PolyHb-SOD-CAT-CA reduced tissue pCO2 from 98 ± 4.5 mmHg to 68.6 ± 3 mmHg. This was significantly (p < 0.05) more effective than lactated Ringer's solution (98 ± 4.5 mmHg), polyHb (90.1 ± 4.0 mmHg), polyHb-SOD-CAT (90.9 ± 1.4 mmHg), blood (79.1 ± 4.7 mmHg), and polySFHb (77 ± 5 mmHg). PolyHb-SOD-CAT-CA reduced the elevated ST level to 21.7 ± 6.7% and is significantly (< 0.05) better than polyHb (57.7 ± 8.7%), blood (39.1 ± 1.5%), polySFHb (38.3% ± 2.1%), polyHb-SOD-CAT (27.8 ± 5.6%), and lactated Ringer's solution (106 ± 3.1%). The plasma cardiac troponin T (cTnT) level of polyHb-SOD-CAT-CA group was significantly (P < 0.05) lower than that of all the other groups. PolyHb-SOD-CAT-CA reduced plasma lactate level from 18 ± 2.3 mM/L to 6.9 ± 0.3 mM/L. It was significantly more effective (P < 0.05) than lactated Ringer's solution (12.4 ± 0.6 mM/L), polyHb (9.6 ± 0.7 mM/L), blood (8.1 ± 0.2 mM/L), polySFHb (8.4 ± 0.1 mM/L), and polyHb-SOD-CAT (7.6 ± 0.3 mM/L). PolyHb-SOD-CAT-CA can be stored for 320 days at room temperature. Lyophilized poly-Hb-SOD-CAT-CA can be heat pasteurized at 68F for 2 h. This can be important if there is a need to inactivate human immunodeficiency virus, Ebola virus, and other infectious organisms.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Erythrocyte Function and Pathophysiology · Heme Oxygenase-1 and Carbon Monoxide
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Artificial Cells and Organs Research Centre, ,
References (35)
Show source-provided references
1. 10.1038/nrd130710.1038/nrd1307 ↗
2. 10.3109/10731199.2011.58105210.3109/10731199.2011.581052 ↗
3. 10.3109/10731199.2013.74529110.3109/10731199.2013.745291 ↗
4. 10.3109/1073119950911797710.3109/10731199509117977 ↗
5. Burhop KE, Estep TE. 2001. Hb induced myocardial lesions. Artif Cells Blood Substit Immobil Biotechnol. 29:101–106.
6. 10.1016/j.transproceed.2004.08.14610.1016/j.transproceed.2004.08.146 ↗
7. Chang TMS (Ed.). 2013. Selected Topics in Nanomedicine. Singapore London: World Science Publisher/Imperial College Press 590 pages.
8. 10.1126/science.146.3643.52410.1126/science.146.3643.524 ↗
9. 10.1016/S0006-291X(71)80260-710.1016/S0006-291X(71)80260-7 ↗
10. Chang TMS. 1997. Red Blood Cell Substitutes: Principles Methods Products and Clinical Trials Vol. I (Monograph). Karger/Landes Systems Basel Switzerland (available for free online viewing at www.medicine.mcgill.ca/artcell).10.1159/isbn.978-3-8055-6584-4 ↗
11. 10.1038/nrd165910.1038/nrd1659 ↗
12. Chang TMS. 2007. Monograph on “ARTIFICIAL CELLS: Biotechnology Nanotechnology Blood Substitutes Regenerative Medicine bioencapsulation cell/stem cell therapy”. Singapore London: World Scientific Publisher/Imperial College Press 454 pages. (available for free online viewing/download at www.medicine.mcgill.ca/artcell).
13. 10.1038/nbt0798-66710.1038/nbt0798-667 ↗
14. 10.1152/physrev.2000.80.2.68110.1152/physrev.2000.80.2.681 ↗
15. 10.1016/0955-3886(95)93436-A10.1016/0955-3886(95)93436-A ↗
16. 10.1080/1073119090274224010.1080/10731190902742240 ↗
17. Hess JR, Johansson PI, Holcomb JB, et al. 2011. Massive transfusion and transfusion therapy in trauma In: Mintz PD, Ed. Transfusion Therapy: Clinical Principles and Practice. 3rd ed. Bethesda, Maryland: AABB Press, pp. 305–322.
18. 10.1097/TA.0b013e318173a93f10.1097/TA.0b013e318173a93f ↗
19. Jia YP Alayash AI. 2013. Molecular Basis of Haptoglobin and Hb Complex Formation and Protection against Oxidative Stress and Damage in “Selected Topics in Nanomedicine” Editor TMS Chang World Science Publisher/Imperial College Press Singapore London 149–168.10.1142/9789814472869_0007 ↗
20. Kim HW Greenburg AG (Eds.). 2014. Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics. New York London: Springer 738 pages10.1007/978-3-642-40717-8 ↗
21. 10.1056/NEJM20000601342221110.1056/NEJM200006013422211 ↗
22. 10.1080/1073119060058023110.1080/10731190600580231 ↗
23. Lui FE, Kluger R. 2011. Reviving artificial blood: meeting the challenge of NO scavenging by hemoglobin. Chem Biochem. 11:1816–1824.
24. 10.1142/9789814472869_000810.1142/9789814472869_0008 ↗
25. 10.1097/MOH.0b013e328347612910.1097/MOH.0b013e3283476129 ↗
26. 10.1016/j.jamcollsurg.2008.09.02310.1016/j.jamcollsurg.2008.09.023 ↗
27. 10.1089/ten.tea.2010.050910.1089/ten.tea.2010.0509 ↗
28. 10.1001/jama.299.19.jrv8000710.1001/jama.299.19.jrv80007 ↗
29. 10.1081/BIO-12000272510.1081/BIO-120002725 ↗
30. 10.1097/00005373-200112000-0002010.1097/00005373-200112000-00020 ↗
31. 10.1088/0967-3334/31/9/01310.1088/0967-3334/31/9/013 ↗
32. Winslow RM (Ed.). 2006. Blood Substitutes. Amsterdam: Academic Press.
33. 10.1080/1073119070158621010.1080/10731190701586210 ↗
34. 10.1097/ALN.0b013e3181cd783810.1097/ALN.0b013e3181cd7838 ↗
35. 10.3109/1073119100363423210.3109/10731191003634232 ↗